Tagged with S

Cyprus In an exclusive interview, President Nicos Anastasiades outlines his public health priorities, the continuing importance of the pharmaceutical industry to Cyprus’s economy, and the nation’s attractiveness as an international investment destination. Ensuring our citizens’ good health is not negotiable. What are your main priorities and policies for public health for…

Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…

Innovation Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research.   “Without patient perspective, there is no good medical product development,” Rachel Sherman, the FDA’s principal deputy commissioner proclaimed during her keynote at last week’s NORD’s Rare Disease & Orphan Products Breakthrough Summit.…

Malaysia Siobhan Das, executive director of the American Malaysian Chamber of Commerce, discusses the close business ties between the two countries and the future opportunities that exist for further investment growth in Malaysia.   What are the main activities of the American Malaysian Chamber of Commerce (AMCHAM)? We’re proud to say…

France Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of the French biological research ecosystem, public-private partnerships, and post-Brexit France.  The CNRS has activity in nearly every field of science…

Spain Oriol Segarra, CEO of Uriach, describes the Spanish OTC company’s recent developments and transformation from a domestic organization to a truly European player.   These are very interesting times for Uriach; the company is celebrating its 180th anniversary, has just won OTC company of the year, and has invested in…

Turkey Cem Kolak, founder and managing director of BL Turkey, the only Turkish Third Party Logistics (3PL) firm 100 percent dedicated to the biopharmaceutical and life sciences sectors, leverages his pioneering experience to provide insights into the development of this niche in Turkey, while sharing with us his ambitions for BL…

Algeria Doria Oughlis, Lilly’s GM for North West Africa, outlines the company’s historic presence in Algeria, current priorities and Lilly’s overarching contribution to the health of the region.   Could you please start by describing Lilly’s legacy in Algeria to date? Lilly’s presence in Algeria actually long predates the setting up…

Malaysia Ch’ng Kien Peng, executive director of Xepa-Soul Pattinson, offers insights on the dynamic healthcare industry in Malaysia and the new government’s key role in supporting the local industry. He also details Xepa-Soul Pattinson’s strong footprint in the country as well as the company’s geographic expansion plans outside of Malaysia.  …

Mexico David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to communicate the complexities of rare diseases simply, we can avoid isolating anyone and the potential to uncover important information is…

Biotech Pfizer has teamed up with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company based in Boston that will focus on developing treatments for a number of central nervous system (CNS) disorders. It has almost been a year since Pfizer announced that they were to cease R&D in new neuroscience…

Japan Pharma Giant Johnson & Johnson (J&J) are set to swallow Ci:z, the Japanese skincare and cosmetics firm.    In a move to really establish themselves within the Asian skin care market, J&J will shell out 230 billion Japanese yen ($2.05 billion) in cash to take over the share of Ci:z…